Sexual Health After Menopause: Libido, Testosterone, and What You Can Actually Do About It

Nobody tells you that menopause can change your relationship with sex. Not just the hot flashes and the vaginal dryness — but the complete disappearance of a desire you took for granted. You used to want sex. Now it's not even on your radar. Your partner thinks it's about them. You wonder if something is wrong with you. You're told it's "just menopause" and that you should accept it.

You don't have to accept it. Sexual health after menopause is a medical issue with medical solutions — not a character flaw or an inevitable consequence of aging.

What Menopause Does to Sexual Function

Sexual function is complex, involving desire (libido), arousal, lubrication, orgasm, and satisfaction. Menopause can affect all of these:

Libido decline. Desire is driven by a combination of hormones, neurotransmitters, relationship factors, and psychological state. Estrogen contributes to overall sexual receptivity. Testosterone — yes, women have it — drives spontaneous desire. Both decline with menopause.

Vaginal dryness and pain. Genitourinary syndrome of menopause (GSM) causes thinning, dryness, and inflammation of vaginal tissues. Sex becomes uncomfortable, then painful. Pain leads to avoidance. Avoidance leads to anxiety about sex. Anxiety leads to more avoidance. The cycle reinforces itself.

Arousal changes. Decreased blood flow to genital tissues reduces arousal response. Clitoral sensitivity may decrease. Time to arousal increases.

Orgasm changes. Orgasm may be less intense, harder to achieve, or take significantly longer. Pelvic floor changes and reduced blood flow contribute.

Relationship dynamics. Menopause doesn't happen in a vacuum. Relationship satisfaction, partner health, communication, stress, body image, and mental health all play roles.

The Testosterone Question

Here's a fact that surprises many women: testosterone is the hormone most directly linked to sexual desire, and women produce it throughout their lives — from the ovaries and adrenal glands.

Testosterone levels peak in the late 20s and decline gradually, reaching approximately 50% of peak levels by menopause. Unlike estrogen, which drops sharply at menopause, testosterone declines slowly — but the loss of ovarian testosterone production after menopause (or surgical oophorectomy) can still be significant.

The evidence for testosterone therapy in women:

A 2019 systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology found that transdermal testosterone therapy in postmenopausal women significantly increased:

• Satisfying sexual events
• Sexual desire
• Arousal
• Orgasm
• Overall sexual function

The effect sizes were clinically meaningful, not just statistically significant.

Current status:

• Testosterone therapy for women is endorsed by multiple international menopause societies
• No testosterone product is FDA-approved for women (though it's widely used off-label)
• Transdermal testosterone (cream or gel) is the preferred delivery method
• Dosing for women is approximately 1/10th of the male dose (targeting female-range testosterone levels, not male levels)
• Monitoring includes testosterone levels, lipids, liver function, and watching for androgenic side effects (acne, hair growth)

At CORAL, Dr. Kim prescribes testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD) when clinically appropriate, with careful dosing and monitoring.

What testosterone won't fix:

• Relationship problems
• Depression-related low libido
• Pain-related sexual avoidance (vaginal dryness needs separate treatment)
• Low desire when you're actually satisfied with your current level of sexual activity

Treating Vaginal Symptoms

If sex hurts, you'll avoid it — regardless of desire. Treating the pain is as important as treating the libido:

Local vaginal estrogen — Creams, tablets, or rings that restore vaginal tissue thickness, lubrication, and elasticity. Low systemic absorption. Safe for most women. This is the cornerstone of GSM treatment.

Vaginal DHEA (prasterone/Intrarosa) — Converts locally to both estrogen and testosterone. Improves both vaginal health and sexual function.

Ospemifene (Osphena) — Oral SERM that treats vaginal dryness without vaginal application. An option for women who prefer oral medication.

Lubricants and moisturizers — Non-prescription options that reduce friction and maintain moisture. Important complements to medical treatment.

Pelvic floor physical therapy — Addresses muscle tension, guarding, and pain patterns that develop secondary to chronic vaginal discomfort.

Beyond Hormones: Other Approaches

Flibanserin (Addyi) and Bremelanotide (Vyleesi)

Two FDA-approved medications for premenopausal HSDD (low desire causing distress):

Flibanserin — Daily oral pill that modulates serotonin and dopamine. Modest benefit (about one additional satisfying sexual event per month). Cannot be used with alcohol. Side effects include dizziness, sleepiness, and low blood pressure.

Bremelanotide — Self-administered injection taken 45 minutes before anticipated sexual activity. Works on melanocortin receptors. Side effects include nausea (40% of women) and injection site reactions.

Both have modest benefits and meaningful side effects. They're approved for premenopausal women only, though off-label use in postmenopausal women occurs.

Psychological Interventions

Cognitive behavioral therapy — Addresses negative thought patterns about sex, body image concerns, performance anxiety, and the emotional aftermath of sexual changes.

Mindfulness-based sex therapy — Teaching present-moment awareness during sexual activity. Particularly helpful for women whose minds wander or who focus on performance rather than sensation.

Couples therapy — When sexual changes create relationship strain, addressing communication, expectations, and intimacy patterns as a couple can be more effective than treating the woman in isolation.

Lifestyle Factors

• Exercise — Regular physical activity improves body image, energy, mood, and blood flow — all of which contribute to sexual function
• Sleep — Sleep deprivation tanks libido. Treat menopause-related sleep disruption.
• Stress management — Chronic stress suppresses sexual desire through cortisol's effects on sex hormones and neurotransmitters
• Medication review — SSRIs, beta-blockers, antihistamines, and other medications can impair sexual function. Dr. Kim can review your medication list for libido-affecting drugs.

Reframing the Conversation

Sexual health in menopause deserves the same clinical attention as cardiovascular health, bone health, or mental health. It's not trivial, it's not superficial, and it's not something you should be embarrassed to discuss with your doctor.

Some important reframes:

Spontaneous desire isn't the only kind. Many postmenopausal women shift from spontaneous desire (wanting sex out of the blue) to responsive desire (becoming interested once sexual activity begins). This is normal, not pathological. It may require rethinking how you initiate intimacy.

Quality over quantity. Sexual satisfaction doesn't always correlate with frequency. Some women are perfectly content with less frequent but more satisfying sexual experiences.

Sex includes more than intercourse. If penetrative sex is painful or undesirable, a broader definition of sexual intimacy can maintain connection and satisfaction.

Your pleasure matters. Many women were socialized to prioritize their partner's pleasure. Menopause is an opportunity to recenter your own experience.

Getting Help

If menopause has changed your sexual health in ways that bother you, there are evidence-based treatments available. You don't have to choose between suffering in silence and accepting it as inevitable.

[Start a visit at coral.clinic/start](https://coral.clinic/start). Dr. Kim provides confidential evaluations for menopause-related sexual health concerns, including hormone assessment, treatment options, and medication management — all via telehealth. Because this conversation shouldn't require sitting in a waiting room.